Latest News

  • Sygnature Discovery Celebrates its 10th Birthday with a Symposium on Aspects of Modern Drug Discovery
    Sygnature Discovery, the United Kingdom’s largest independent provider of integrated drug discovery resource and expertise, celebrated its 10th anniversary by hosting a symposium on “Aspects of Modern Drug Discovery”. Held at Nottingham’s East Midlands Conference Centre, the symposium welcomed distinguished scientific speakers from around the country to a packed audience of 200 guests.
  • New TSRI Studies Bring Scientists Closer to Combating Dangerous Unstable Proteins
    Scientists from The Scripps Research Institute (TSRI) have discovered new techniques to reduce protein deposits accumulating in key organs, causing a potentially deadly set of human diseases known as systemic amyloid diseases. Luke Wiseman, assistant professor at TSRI and a senior author of the new research, describes how a strategy to reduce the load coming from these proteins could open up treatment options that could be broadly applied to treat multiple systemic amyloid diseases.
  • £230 million for technologies to revolutionise research into disease
    The Chancellor of the Exchequer, George Osborne, has today (Thursday 23 October) announced that a partnership led by the Medical Research Council (MRC) will invest over £230 million in a range of revolutionary technologies aimed at identifying the causes of diseases such as cancer and dementia, and dramatically speeding up diagnosis and treatment. The state-of-the-art technologies will be used to find out how differences in the cellular and molecular make-up of people affect how they respond to diseases and to treatment.
  • Auspherix and Domainex Announce Collaboration to Develop New Drugs to Treat Antibiotic-resistant Bacterial Infections
    Domainex Ltd. and Auspherix Pty Ltd today announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate. Auspherix intends to develop much-needed new drugs to fight the increasing problem of antibiotic-resistant bacterial infections, which have been widely reported as one of the most significant threats to patients' safety across the world.*
  • The Current issue of “The view from here” discusses allosterism in drug discovery.
    The topic of this month’s newsletter from Drug Discovery Today is allosterism in drug discovery.
view more

Podcasts

view more

Webinars

  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more

Features

view more

Downloads

view more

25 Hottest Articles

view more